The cytokine trio - visfatin, placental growth factor and fractalkine – and their role in myocardial infarction with non-obstructive coronary arteries (MINOCA)
Authors:
Open Access
- 25 August 2023
- journal article
- review article
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 74, 76-85
Abstract
No abstract availableKeywords
Funding Information
- Narodowe Centrum Nauki (2021/05/X/NZ5/01609)
- Narodowe Centrum Nauki (MINIATURA -5)
This publication has 93 references indexed in Scilit:
- Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapyTrends in Pharmacological Sciences, 2012
- The discovery of placenta growth factor and its biological activityExperimental & Molecular Medicine, 2012
- Fractalkine Is a Novel Human Adipochemokine Associated With Type 2 DiabetesDiabetes, 2011
- RACK1 Regulates VEGF/Flt1-mediated Cell Migration via Activation of a PI3K/Akt PathwayJournal of Biological Chemistry, 2011
- Fractalkine/CX3CL1: A Potential New Target for Inflammatory DiseasesMolecular Interventions, 2010
- Placenta Growth Factor-induced Early Growth Response 1 (Egr-1) Regulates Hypoxia-inducible Factor-1α (HIF-1α) in Endothelial CellsJournal of Biological Chemistry, 2010
- Regulation of hypoxia-inducible factor-1α by NF-κBBiochemical Journal, 2008
- Placental growth factor is a potent vasodilator of rat and human resistance arteriesAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Nampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic EnzymeCell Metabolism, 2007
- Increased Expression of Visfatin in Macrophages of Human Unstable Carotid and Coronary AtherosclerosisCirculation, 2007